These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28620791)

  • 1. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Low Urin Tract Symptoms; 2018 Sep; 10(3):215-220. PubMed ID: 28436145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
    Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
    Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
    Nitti VW; Chapple CR; Walters C; Blauwet MB; Herschorn S; Milsom I; Auerbach S; Radziszewski P
    Int J Clin Pract; 2014 Aug; 68(8):972-85. PubMed ID: 24703195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
    Sidaway P
    Nat Rev Urol; 2015 Nov; 12(11):593. PubMed ID: 26345211
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
    Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
    Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.